

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/726,216
				Filing Date	12/2/2003
				First Named Inventor	Nichols et al.
				Art Unit	1646
				Examiner Name	Marianne P. Allen
Sheet	1	of	3	Attorney Docket Number	421/29/2/2 CIP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-7,041,475	05-09-2006	Nichols et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	2	WO 9504822	02-16-1995	Salk Institute Biotech Ind. Assoc. Ltd.		
	3	WO 02/063000	08-15-2002	UNC-Chapel Hill		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/726,216
				<i>Filing Date</i>	12/2/2003
				<i>First Named Inventor</i>	Nichols et al.
				<i>Art Unit</i>	1646
				<i>Examiner Name</i>	Marianne P. Allen
(Use as many sheets as necessary)				<i>Attorney Docket Number</i>	421/29/2/2 CIP
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	Bork et al., "Trends in Genetics," Vol. 12, pgs. 425-427 (1996).	
	5	Brenner, "Trends in Genetics," Vol. 15, pgs. 132-133 (1999).	
	6	Commonly-assigned U.S. Patent Application Serial No. 10/029,413 for "PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS," published as U.S. Patent Publication No. 2002/0165353, now Patent No. 7,041,475.	
	7	Doerks et al., "Protein annotation: detective work for function prediction. Trends in Genetics," Vol. 14, No. 6, pgs. 248-250 (June 1998).	
	8	Ihara, Yu et al., <i>Rat rCACN4A mRNA for L-type Voltage Dependent Calcium Channel Alpha 1 Subunit</i> , Database accession no. D38101 XP002238191 (Abstract) (March 29, 1995).	
	9	Ihara, Yu et al., <i>Voltage-dependent L-type Voltage Calcium Channel Alpha 1D Subunit (Rat)</i> , Database accession no. P27732 XP002238193 (Abstract) (October 1, 1996).	
	10	Mickle et al., "Genotype-phenotype relationships in cystic fibrosis," Med. Clin. North Am., Vol. 84, No. 3, pgs. 597-607 (May 2000).	
	11	Notice of Allowance corresponding to U.S. Patent Application Serial No. 10/029,413 (Patent No. 7,041,475) dated October 18, 2005.	
	12	Official Communication corresponding to U.S. Patent Application Serial No. 10/029,413 (Patent No. 7,041,475) dated March 8, 2004.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/726,216
				Filing Date	12/2/2003
				First Named Inventor	Nichols et al.
				Art Unit	1646
				Examiner Name	Marianne P. Allen
Sheet	3	of	3	Attorney Docket Number	421/29/2/2 CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	13	Official Communication corresponding to U.S. Patent Application Serial No. 10/029,413 (Patent No. 7,041,475) dated August 11, 2004.	
	14	Official Communication corresponding to U.S. Patent Application Serial No. 10/029,413 (Patent No. 7,041,475) dated May 17, 2005.	
	15	Seino, S. et al., <i>Human neuroendocrine/beta-cell-type calcium channel alpha-1 subunit mRNA</i> , Database accession no. M83566 XP002238192 (Abstract) (February 3, 1992).	
	16	Stratagene Catalog, pg. 39 (1988).	
	17	Voet et al., "Biochemistry," John Wiley & Sons, Inc., pgs. 126-128 and 228-234 (1990).	
	18	Yan et al., "Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors," <i>Science</i> , Vol. 290, pgs. 523-527 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.